Mode
Text Size
Log in / Sign up

Hyperhomocysteinemia is associated with a higher risk of silent brain infarcts in patientsHigh homocysteine levels linked to increased risk of silent brain infarcts

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that hyperhomocysteinemia is associated with increased silent brain infarct risk, especially at levels >12 µmol/L.

This meta-analysis evaluated the relationship between hyperhomocysteinemia and silent brain infarcts in a population of 2331 patients. The analysis synthesized data from observational studies to determine the association between homocysteine levels and neurological outcomes.

The primary finding was an increased rate of image-confirmed silent brain infarcts in patients with hyperhomocysteinemia (23.4%) compared to controls (22.8%), with an OR of 1.84 (95% CI 1.09-3.11; P = 0.02). This association was significantly stronger in studies using a cutoff of >12 µmol/L, which showed an OR of 3.08 (95% CI 1.85-5.11; P < 0.0001). Regarding secondary outcomes, patients with hyperhomocysteinemia showed numerically lower cognitive performance on the Mini-Mental State Examination (mean difference -1.55; 95% CI -3.60-0.50; P = 0.14).

The authors note that the evidence is limited by the inclusion of observational studies. While the data suggest a link between hyperhomocysteinemia and silent brain infarcts, prospective studies are required to determine if homocysteine represents a modifiable therapeutic target. Clinical application is currently limited by the lack of evidence regarding causality.

How this fits prior evidence

This meta-analysis addresses a gap in understanding the role of metabolic factors in stroke risk. It provides evidence that hyperhomocysteinemia is associated with an increased risk of silent brain infarcts. This finding relates to the Neuroprotective anesthesia targets protocol, which aims to reduce silent brain infarction and perioperative neurocognitive disorders, though that protocol has not yet yielded results.

Silent brain infarcts are small strokes that happen without obvious symptoms, but they can still impact brain health over time. A large review of data involving over 2,300 people looked at how homocysteine—a compound in the blood—relates to these silent events. The researchers found that people with high homocysteine levels had a higher rate of these silent infarcts compared to those with normal levels.

The link became even more noticeable in cases where homocysteine levels were particularly high. While the study also looked at cognitive performance, the results for mental clarity were only numerically lower for those with high levels, and this specific finding was not statistically significant.

It is important to note that these findings come from observational studies, which show a connection but do not prove that one thing causes the other. More research is needed to see if lowering homocysteine can be a practical way to protect the brain. Talk to your doctor if you have concerns about your blood levels or brain health.

What this means for you:
High homocysteine levels are linked to a higher risk of silent brain infarcts, especially at higher concentrations.

Common questions

What is a silent brain infarct?

A silent brain infarct is a small stroke that does not cause immediate, noticeable symptoms. Even though you might not feel it happening, these events can still affect your brain health over time. This study looked at how homocysteine levels relate to the rate of these specific events.

How does homocysteine affect the brain in this study?

The study found that people with high homocysteine levels had a higher rate of silent brain infarcts compared to those with normal levels. This risk was even higher in cases where homocysteine levels were above 12 micromoles per liter. However, the study only shows a connection, not a direct cause.

Does high homocysteine affect memory or thinking?

The study measured cognitive performance using a standard test. While those with high homocysteine levels had numerically lower scores, the difference was not statistically significant. Because these were observational studies, more research is needed to understand the full impact on the brain.

Study Details

Study typeMeta analysis
Sample sizen = 2,331
EvidenceLevel 1
Follow-up76.8 mo
PublishedSep 2026
View Original Abstract ↓
BACKGROUND AND PURPOSE: Previous studies have reported differences in homocysteine levels between patients with and without silent brain infarction. However, evidence comparing silent brain infarct rates by hyperhomocysteinemia status remains limited. We conducted a systematic review and meta-analysis comparing silent brain infarct rates in patients with hyperhomocysteinemia versus normal homocysteine levels. METHODS: A systematic literature search was conducted from inception to June 17, 2025. Eligible studies compared the rate of image-confirmed silent brain infarcts in patients with hyperhomocysteinemia versus those with normal homocysteine levels. The primary outcome was the rate of silent brain infarcts, and the secondary outcome was cognitive performance assessed by the Mini-Mental State Examination (MMSE). Pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated using a random-effects model, with heterogeneity assessed using I² statistics. Subgroup analyses were performed according to hyperhomocysteinemia cutoffs (>12 µmol/L and 9-12 µmol/L) as defined in the included studies. RESULTS: Four observational studies involving 2331 patients were included (mean age 58.0±6.4 years; 45.8% women). Of these, 1087 had hyperhomocysteinemia and 1244 had normal levels. The rate of silent brain infarcts was 23.4% (253/1087) in patients with hyperhomocysteinemia versus 22.8% (284/1244) in controls (OR 1.84; 95% CI 1.09-3.11; P = 0.02). The association was higher in studies using a >12 µmol/L cutoff (OR 3.08; 95% CI 1.85-5.11; P < 0.0001). MMSE scores were numerically lower in patients with hyperhomocysteinemia but did not differ significantly from controls (mean difference -1.55; 95% CI -3.60-0.50; P = 0.14). CONCLUSIONS: Hyperhomocysteinemia is associated with an increased risk of silent brain infarcts and numerically lower cognitive performance. Findings suggest that the association between homocysteine and silent brain infarction may be stronger at higher homocysteine levels. Prospective studies are needed to determine whether homocysteine is a modifiable therapeutic target for reducing silent infarcts and cognitive decline.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.